Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,325 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donor-derived gene mutations in sex chromosome loss after stem cell transplantation.
Adachi H, Sadato D, Toya T, Hirama C, Haraguchi K, Mukae J, Shingai N, Shimizu H, Najima Y, Kobayashi T, Okuyama Y, Oboki K, Harada H, Sakamaki H, Ohashi K, Harada Y, Doki N. Adachi H, et al. Among authors: shimizu h. Br J Haematol. 2021 Nov;195(3):e142-e146. doi: 10.1111/bjh.17716. Epub 2021 Jul 27. Br J Haematol. 2021. PMID: 34312849 No abstract available.
Prognostic impact of cytogenetic abnormalities in adult patients with Philadelphia chromosome-negative ALL who underwent an allogeneic transplant.
Shimizu H, Doki N, Kanamori H, Sakura T, Mori T, Machida S, Takahashi S, Ohwada C, Fujisawa S, Yano S, Hagihara M, Kanda Y, Onoda M, Gotoh M, Kako S, Taguchi J, Usuki K, Kawai N, Aotsuka N, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Bone Marrow Transplant. 2019 Dec;54(12):2020-2026. doi: 10.1038/s41409-019-0585-2. Epub 2019 Jun 11. Bone Marrow Transplant. 2019. PMID: 31186516
[Tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma: real-world data from single institute experience].
Yagi Y, Kanemasa Y, Sasaki Y, Hayashi Y, Mino M, Kato C, Sakai S, Ohigashi A, Kanbara Y, Morita Y, Tamura T, Atsuta Y, Konuma R, Nakamura S, Wada A, Okuya T, Kageyama A, Murakami D, Nakashima S, Uchibori Y, Onai D, Hamamura A, Nishijima A, Omuro Y, Shingai N, Shimizuguchi T, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Ohashi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: shimizu h. Rinsho Ketsueki. 2022;63(10):1363-1372. doi: 10.11406/rinketsu.63.1363. Rinsho Ketsueki. 2022. PMID: 36351641 Japanese.
A third dose of COVID-19 mRNA vaccine induces limited humoral response in stem cell transplant recipients who got two vaccine doses before transplant.
Toya T, Sadato D, Sanada T, Honda T, Atsuta Y, Sekiya N, Shimizu H, Najima Y, Kobayashi T, Harada Y, Kohara M, Doki N. Toya T, et al. Among authors: shimizu h. EJHaem. 2022 Dec 22;4(1):309-11. doi: 10.1002/jha2.637. Online ahead of print. EJHaem. 2022. PMID: 36721642 Free PMC article. No abstract available.
Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A Kanto Study Group for Cell Therapy multicenter analysis.
Harada K, Onizuka M, Mori T, Shimizu H, Seo S, Aotsuka N, Takeda Y, Sekiya N, Kusuda M, Fujiwara S, Shiraiwa S, Shono K, Shingai N, Kanamori H, Momoki M, Takada S, Mukae J, Masuda S, Mitani K, Sakaida E, Tomikawa T, Takahashi S, Usuki K, Kanda Y. Harada K, et al. Among authors: shimizu h. Int J Infect Dis. 2023 Jun;131:79-86. doi: 10.1016/j.ijid.2023.03.045. Epub 2023 Mar 29. Int J Infect Dis. 2023. PMID: 37001798 Free article.
Clinical significance of late CMV disease in adult patients who underwent allogeneic stem cell transplant.
Shimizu H, Najima Y, Kako S, Tanaka M, Fujiwara SI, Mori T, Usuki K, Gotoh M, Hagihara M, Tsukada N, Oniduka M, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Yano S, Ohashi K, Takahashi S, Okamoto S, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. J Infect Chemother. 2023 Dec;29(12):1103-1108. doi: 10.1016/j.jiac.2023.07.015. Epub 2023 Aug 1. J Infect Chemother. 2023. PMID: 37532223
[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y, Yagi Y, Kanemasa Y, Sasaki Y, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Ohashi K, Shimoyama T. Morita Y, et al. Among authors: shimizu h. Rinsho Ketsueki. 2023;64(7):586-595. doi: 10.11406/rinketsu.64.586. Rinsho Ketsueki. 2023. PMID: 37544717 Japanese.
Clinical outcomes in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: A retrospective study.
Yagi Y, Kanemasa Y, Sasaki Y, Sei M, Matsuo T, Ishimine K, Hayashi Y, Mino M, Ohigashi A, Morita Y, Tamura T, Nakamura S, Okuya T, Shimizuguchi T, Shingai N, Toya T, Shimizu H, Najima Y, Kobayashi T, Haraguchi K, Doki N, Okuyama Y, Shimoyama T. Yagi Y, et al. Among authors: shimizu h. Cancer Med. 2023 Sep;12(17):17808-17821. doi: 10.1002/cam4.6412. Epub 2023 Aug 28. Cancer Med. 2023. PMID: 37635630 Free PMC article.
Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation.
Kambara Y, Sadato D, Toya T, Honda A, Kato S, Hirama C, Haraguchi K, Shimizu H, Najima Y, Kobayashi T, Okuyama Y, Harada H, Takahashi S, Kurokawa M, Harada Y, Doki N. Kambara Y, et al. Among authors: shimizu h. Leukemia. 2024 Mar;38(3):667-670. doi: 10.1038/s41375-024-02152-7. Epub 2024 Jan 18. Leukemia. 2024. PMID: 38238444 No abstract available.
6,325 results